AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10534038 — intervention group
Group type: EXPERIMENTAL
Intervention: Scandinavian vacuum mattress with a vacuum collar
Number of subjects: 39
Study 8890804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of dipyridamole
Number of subjects: 20
Study 1985721 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP chemotherapy (vincristine, doxorubicin, and prednisone) with radiotherapy for local relapse
Number of subjects: 98
Study 1985721 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug intrathecal therapy and regimens of 6-thioguanine and cytarabine alternating with vincristine, prednisone, cyclophosphamide, and cytarabine
Number of subjects: 98
Study 1985721 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for testicular relapse
Number of subjects: 98
Study 6368649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ASA treatment
Number of subjects: 25
Study 6368649 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 6368649 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization to ASA followed by ASA treatment
Number of subjects: 25
Study 31328425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer plus financial education programme
Number of subjects: 80
Study 29952408 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous propofol anaesthesia (TIVA), n = 31
Number of subjects: 61
Study 29952408 — intervention group
Group type: COMPARATOR
Intervention: Volatile induction and maintenance sevoflurane anaesthesia (VIMA), n = 30
Number of subjects: 61
Study 26473667 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 30 mg BID + Asunaprevir (ASV) 200 mg BID + Beclabuvir (BCV) 150 mg BID
Number of subjects: 187
Study 26473667 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Asunaprevir (ASV) + Beclabuvir (BCV) with ribavirin
Number of subjects: 187
Study 26473667 — intervention group
Group type: COMPARATOR
Intervention: Daclatasvir (DCV) + Asunaprevir (ASV) + Beclabuvir (BCV) without ribavirin
Number of subjects: 187
Study 24446153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 84
Study 24446153 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 84
Study 22821643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.05%
Number of subjects: 18
Study 22821643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1%
Number of subjects: 18
Study 22821643 — intervention group
Group type: COMPARATOR
Intervention: Saline (sodium chloride 0.9%)
Number of subjects: 18
Study 20374607 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly cytological screening in primary care
Number of subjects: 4439
Study 20374607 — intervention group
Group type: COMPARATOR
Intervention: Referral for colposcopy
Number of subjects: 4439
Study 20374607 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing for detection of CIN2 or worse
Number of subjects: 4439
Study 20374607 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 4439
Study 16926382 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal ADP stimulated respiration with FA-derived substrate (palmitoyl-l-carnitine + malate)
Number of subjects: 13
Study 16926382 — intervention group
Group type: EXPERIMENTAL
Intervention: MFO (maximal fatty acid oxidation)
Number of subjects: 13
Study 16926382 — intervention group
Group type: EXPERIMENTAL
Intervention: MFO during submaximal exercise at 80 W
Number of subjects: 13
Study 16926382 — intervention group
Group type: EXPERIMENTAL
Intervention: MFO during submaximal exercise at 120 W
Number of subjects: 13
Study 16926382 — intervention group
Group type: EXPERIMENTAL
Intervention: MFO interpolated at 35% Vo(2 peak)
Number of subjects: 13
Study 16926382 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP sensitivity of mitochondrial respiration with FA-derived substrate
Number of subjects: 13
Study 17663288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers (n=50)
Number of subjects: 100
Study 17663288 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (n=50)
Number of subjects: 100
Study 14964744 — intervention group
Group type: EXPERIMENTAL
Intervention: efalizumab 1.0 mg/kg/wk
Number of subjects: 1242
Study 14964744 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1242
Study 11179987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) with clarithromycin
Number of subjects: 145
Study 11179987 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole with clarithromycin
Number of subjects: 145
Study 11179987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC)
Number of subjects: 145
Study 11179987 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 145
Study 9379635 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable plate-haptic silicone IOL (Chiron Adatomed, C10)
Number of subjects: 67
Study 9379635 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable disc silicone IOL (Chiron Adatomed, 90D)
Number of subjects: 67
Study 9379635 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece PMMA-IOL (Pharmacia & Upjohn, 809C)
Number of subjects: 67
Study 8472233 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TFE
Number of subjects: 44
Study 8472233 — intervention group
Group type: COMPARATOR
Intervention: ePTFE
Number of subjects: 44
Study 3898805 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms Cr3+ as chromic chloride (CrCl3)
Number of subjects: 23
Study 3898805 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g brewer's yeast
Number of subjects: 23
Study 3898805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11251917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal translucency (NT) measurements
Number of subjects: 879
Study 11251917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal translucency (NT) measurements expressed by MoM values
Number of subjects: 879
Study 11251917 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative data of fetal NT thickness
Number of subjects: 879
Study 31029436 — intervention group
Group type: EXPERIMENTAL
Intervention: 5HIAA levels in cerebrospinal fluid (CSF) for PE group (IELT < 1 min)
Number of subjects: 60
Study 31029436 — intervention group
Group type: COMPARATOR
Intervention: 5HIAA levels in cerebrospinal fluid (CSF) for control group (IELT > 1 min)
Number of subjects: 60
Study 31029436 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between IELT and 5HIAA levels
Number of subjects: 60
Study 31029436 — intervention group
Group type: COMPARATOR
Intervention: Comparison of average 5HIAA levels between PE and control groups
Number of subjects: 60
Study 30270794 — intervention group
Group type: EXPERIMENTAL
Intervention: Borehole drilling
Number of subjects: 0
Study 30270794 — intervention group
Group type: EXPERIMENTAL
Intervention: Borehole rehabilitation
Number of subjects: 0
Study 30270794 — intervention group
Group type: COMPARATOR
Intervention: Borehole drilling and rehabilitation
Number of subjects: 0
Study 26895895 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure with endoscopic clips
Number of subjects: 28
Study 26895895 — intervention group
Group type: COMPARATOR
Intervention: Non-closure
Number of subjects: 28
Study 25056981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 80
Study 22290273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily for 21 days followed by single-dose ridaforolimus 40 mg on day 14
Number of subjects: 0
Study 22290273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg daily for 14 days followed by single-dose ridaforolimus 2 mg on day 2
Number of subjects: 0
Study 21171773 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Ecosystems Therapy (SET)
Number of subjects: 67
Study 21171773 — intervention group
Group type: COMPARATOR
Intervention: Health Group (HG)
Number of subjects: 67
Study 17935597 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus memory restructuring intervention
Number of subjects: 45
Study 17935597 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study 16022174 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage adaptive design for clinical trials with survival data
Number of subjects: 0
Study 16022174 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumadin Aspirin Reinfarction Study
Number of subjects: 0
Study 12022509 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible parametric techniques for regression analysis using feed forward artificial neural networks (FFANNs)
Number of subjects: 0
Study 12022509 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer perceptron and radial basis function extensions of generalized linear models for survival data
Number of subjects: 0
Study 10434166 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline administration (6 mg kg‐1 infused over 7.5 min)
Number of subjects: 34
Study 7607766 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol 200‐400 mg/day
Number of subjects: 40
Study 7607766 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100‐200 mg/day
Number of subjects: 40
Study 2094056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone substitution and Cavinton adjuvant therapy
Number of subjects: 40
Study 2094056 — intervention group
Group type: COMPARATOR
Intervention: Hormone substitution therapy
Number of subjects: 40
Study 332369 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 150
Study 332369 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 150
Study 31994954 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care plus asthma intervention program
Number of subjects: 63
Study 31994954 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive care alone
Number of subjects: 63
Study 31179002 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV-supported ACT
Number of subjects: 14
Study 31179002 — intervention group
Group type: COMPARATOR
Intervention: ACT alone
Number of subjects: 14
Study 29174618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibered Platinum Coils (FPCs)
Number of subjects: 100
Study 29174618 — intervention group
Group type: COMPARATOR
Intervention: Vascular Plugs (VPs)
Number of subjects: 100
Study 25165064 — intervention group
Group type: EXPERIMENTAL
Intervention: RECT[active] + rTMS[active] (Group-A)
Number of subjects: 36
Study 25165064 — intervention group
Group type: COMPARATOR
Intervention: RECT[sham] + rTMS[active] (Group-B)
Number of subjects: 36
Study 25165064 — intervention group
Group type: COMPARATOR
Intervention: RECT[active] + rTMS[sham] (Group-C)
Number of subjects: 36
Study 24337077 — intervention group
Group type: EXPERIMENTAL
Intervention: 15C (payment contingent on smoking abstinence across all 15 study days)
Number of subjects: 0
Study 24337077 — intervention group
Group type: COMPARATOR
Intervention: 2C (payment contingent on smoking abstinence for just the final 2 days)
Number of subjects: 0
Study 24337077 — intervention group
Group type: EXPERIMENTAL
Intervention: 15C
Number of subjects: 0
Study 24337077 — intervention group
Group type: COMPARATOR
Intervention: 2C
Number of subjects: 0
Study 23061804 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 0
Study 20061926 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 47
Study 20061926 — intervention group
Group type: COMPARATOR
Intervention: other hypotensives
Number of subjects: 47
Study 17525087 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, leucovorin, 5‐fluorouracil and etoposide (ELFE regimen)
Number of subjects: 228
Study 17525087 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 228
Study 17525087 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, leucovorin, 5‐fluorouracil and etoposide (ELFE regimen) in node-positive patients
Number of subjects: 228
Study 17525087 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone in node-positive patients
Number of subjects: 228
Study 15766366 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) b.i.d. for 3 months
Number of subjects: 35
Study 15766366 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. for 3 months
Number of subjects: 35
Study 15766366 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 35
Study 15766366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 14670773 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) treatment, 1 IU/kg/week, administered via daily subcutaneous injections for 12 months.
Number of subjects: 20
Study 14670773 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 20
Study 10620211 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine
Number of subjects: 59
Study 10620211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8880055 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10, 20, 40, 80 mg)
Number of subjects: 24
Study 8880055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (3-week intervals)
Number of subjects: 24
Study 8880055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25, 50, 100, 200 mg)
Number of subjects: 24
Study 8880055 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10, 20, 40, 80 mg)
Number of subjects: 24
Study 1804757 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole alone for 4 weeks
Number of subjects: 0
Study 1804757 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus roxithromycin for 2 weeks
Number of subjects: 0
Study 6347173 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment
Number of subjects: 45
Study 6347173 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study 6347173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (antacid and placebo)
Number of subjects: 45
Study 6347173 — intervention group
Group type: EXPERIMENTAL
Intervention: Climbers with severe AMS symptoms
Number of subjects: 45
Study 28531324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette depicting a grandparent in need
Number of subjects: 989
Study 28531324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette depicting a grandchild in need
Number of subjects: 989
Study 28531324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette granddaughter
Number of subjects: 989
Study 28531324 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who are single, in worse functional health, and whose children all migrated
Number of subjects: 989
Study 28531324 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who coresided with children
Number of subjects: 989
Study 30459575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Electrical Stimulation (EIMS) at 2 Hz for ten sessions
Number of subjects: 24
Study 30459575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Electrical Stimulation (EIMS)
Number of subjects: 24
Study 30459575 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 24
Study 26086325 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching device
Number of subjects: 21
Study 26086325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 24556829 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐energy diet (800‐1,000 kcal/day for 8 weeks followed by 1,200 kcal/day for 8 weeks)
Number of subjects: 60
Study 24556829 — intervention group
Group type: COMPARATOR
Intervention: normal healthy foods (for 16 weeks)
Number of subjects: 60
Study 24556829 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐energy diet
Number of subjects: 60
Study 24556829 — intervention group
Group type: COMPARATOR
Intervention: normal healthy foods
Number of subjects: 60
Study 21931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal every-other-day OL-HDF (same convective volume for 6 months)
Number of subjects: 26
Study 21931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal every-other-day OL-HDF (higher convective volume for 6 months)
Number of subjects: 26
Study 21931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal every-other-day OL-HDF
Number of subjects: 26
Study 19969021 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780
Study 19969021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 17947823 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian HP60M IOL
Number of subjects: 600
Study 17947823 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof MA60BM IOL
Number of subjects: 600
Study 17947823 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof MA30BA IOL
Number of subjects: 600
Study 17947823 — intervention group
Group type: EXPERIMENTAL
Intervention: AMO Clariflex IOL
Number of subjects: 600
Study 17947823 — intervention group
Group type: COMPARATOR
Intervention: All IOLs
Number of subjects: 600
Study 16238217 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Number of subjects: 15
Study 16238217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Number of subjects: 15
Study 16238217 — intervention group
Group type: COMPARATOR
Intervention: Both conventional and ART methods
Number of subjects: 15
Study 16238217 — intervention group
Group type: COMPARATOR
Intervention: Failures in restorations
Number of subjects: 15
Study 16238217 — intervention group
Group type: COMPARATOR
Intervention: Conventional and ART methods
Number of subjects: 15
Study 12404887 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dequalinium chloride, treated once per day for 6 days
Number of subjects: 180
Study 12404887 — intervention group
Group type: COMPARATOR
Intervention: 200 mg povidone iodine, treated once per day for 6 days
Number of subjects: 180
Study 9593495 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR) and therapy (PT and OT)
Number of subjects: 24
Study 9593495 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving physiotherapy (PT) and occupational therapy (OT)
Number of subjects: 24
Study 7836712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol withdrawal for 1 week
Number of subjects: 16
Study 2963509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone premedication
Number of subjects: 82
Study 2963509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 31243480 — intervention group
Group type: EXPERIMENTAL
Intervention: RGB-10
Number of subjects: 250
Study 31243480 — intervention group
Group type: COMPARATOR
Intervention: Reference teriparatide
Number of subjects: 250
Study 30721201 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinalamine (#10, intramuscularly, one course)
Number of subjects: 146
Study 30721201 — intervention group
Group type: COMPARATOR
Intervention: Traditional neuroprotective therapy
Number of subjects: 146
Study 26747497 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with carotid artery disease
Number of subjects: 60
Study 26747497 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 60
Study 24622716 — intervention group
Group type: EXPERIMENTAL
Intervention: SYR-472 12.5 mg
Number of subjects: 322
Study 24622716 — intervention group
Group type: EXPERIMENTAL
Intervention: SYR-472 25 mg
Number of subjects: 322
Study 24622716 — intervention group
Group type: EXPERIMENTAL
Intervention: SYR-472 50 mg
Number of subjects: 322
Study 24622716 — intervention group
Group type: EXPERIMENTAL
Intervention: SYR-472 100 mg
Number of subjects: 322
Study 24622716 — intervention group
Group type: EXPERIMENTAL
Intervention: SYR-472 200 mg
Number of subjects: 322
Study 24622716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 23011525 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (valsartan or amlodipine)
Number of subjects: 10545
Study 23011525 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (including hydrochlorothiazide)
Number of subjects: 10545
Study 23011525 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy controlled vs uncontrolled
Number of subjects: 10545
Study 19930237 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Friendship Training (CFT)
Number of subjects: 100
Study 19930237 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 100
Study 17350216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo-ecraprost (60-microg dose administered intravenously starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)
Number of subjects: 322
Study 17350216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)
Number of subjects: 322
Study 17350216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 17350216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo-ecraprost
Number of subjects: 322
Study 17350216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo-ecraprost and Placebo
Number of subjects: 322
Study 16333148 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training with visual feedback, three sessions per week for six weeks
Number of subjects: 10
Study 16333148 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training with visual feedback
Number of subjects: 10
Study 16333148 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 12490752 — intervention group
Group type: EXPERIMENTAL
Intervention: Study care protocol (no-rinse skin cleanser after each episode and application of a barrier cream with durable properties after the first incontinence episode of each shift)
Number of subjects: 32
Study 12490752 — intervention group
Group type: COMPARATOR
Intervention: Standard care regimen (soap and water cleansing after each incontinence episode, followed by application of a moisturizing lotion)
Number of subjects: 32